Clinical Trial

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to see how orforglipron, compared with placebo, helps reduce body weight in participants with obesity or with overweight and at least one other related health condition (excluding type 2 diabetes). This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.
Protocol Amendment History 3 changes
notable Enrollment increased: 600 -> 800 participants 2026-07-30
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-25
notable Primary completion pushed: 2027-01 -> 2027-08 2026-04-17
Trial Details
NCT Number NCT06972459
Lead Sponsor Eli Lilly and Company
Conditions Obesity, Overweight
Enrollment 800 participants
Start Date 2025-05-15
Primary Completion 2027-08 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-29